X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate which is being evaluated in phase 3 clinical trials for the treatment of previously treated patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors.
Lead Product(s): Trastuzumab Deruxtecan
Therapeutic Area: Oncology Product Name: Enhertu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
R-DXd (raludotatug deruxtecan) potential first-in-class CDH6 directed DXd antibody drug conjugate. It is being evaluated for the treatment of patients with platinum-resistant ovarian cancer.
Lead Product(s): Raludotatug Deruxtecan
Therapeutic Area: Oncology Product Name: R-DXd
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
Dato-DXd (datopotamab deruxtecan) is an investigational TOP1 & TROP2 directed ADC comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, which is being evaluated for the treatment of advanced HR positive, HER2 negative breast cancer.
Lead Product(s): Datopotamab Deruxtecan
Therapeutic Area: Oncology Product Name: Dato-DXd
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
Nilemdo(bempedoic acid) is an adenosine triphosphate-citrate lyase (ACL) inhibitor indicated as an adjunct to diet and statin therapy for the treatment of heart attack, hypercholesterolaemia & cardiovascular diseases.
Lead Product(s): Bempedoic Acid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nilemdo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
Dato-DXd (datopotamab deruxtecan) is an investigational TOP1 & TROP2 directed ADC comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, which is being evaluated for the treatment of advanced HR positive, HER2 negative breast cancer.
Lead Product(s): Datopotamab Deruxtecan
Therapeutic Area: Oncology Product Name: Dato-DXd
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
Under the expiration of the agreement, Daiichi will transfer the distribution rights of Tenelia (teneligliptin) to Mitsubishi and will end the information provision activities to medical institutions for all products, which are currently jointly conducted with Mitsubishi.
Lead Product(s): Teneligliptin
Therapeutic Area: Endocrinology Product Name: Tenelia
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Mitsubishi Tanabe Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination March 04, 2024
Details:
DS-1062a (datopotamab deruxtecan) is a TROP2-directed DXd antibody-drug conjugate. It is currently being evaluated in the Phase III clinical studies for the treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer and HR Positive/HER2 Negative breast cancer.
Lead Product(s): Datopotamab Deruxtecan
Therapeutic Area: Oncology Product Name: DS-1062a
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
DS-1062a (datopotamab deruxtecan) is an investigational TOP1 & TROP2 directed ADC comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, which is being evaluated for the treatment of advanced nonsquamous non-small cell lung cancer.
Lead Product(s): Datopotamab Deruxtecan
Therapeutic Area: Oncology Product Name: DS-1062a
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
Ezharmia (valemetostat tosilate) is a first-in-class dual inhibitor of EZH1 and EZH2. It is being evaluated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: Ezharmia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate which is being evaluated in phase 3 clinical trials for the treatment of patients with unresectable or metastatic HER2-expressing advanced solid tumours.
Lead Product(s): Deruxtecan
Therapeutic Area: Oncology Product Name: Enhertu
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
